| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/02/2000 | WO2000031081A2 Amino- and mercurio-substituted 4',5'-dihydropsoralens and therapeutical uses thereof |
| 06/02/2000 | WO2000031070A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same |
| 06/02/2000 | WO2000031068A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 06/02/2000 | WO2000031067A1 Propanoic acid derivatives as integrin inhibitors |
| 06/02/2000 | WO2000031065A1 Compounds having cytokine inhibitory activity |
| 06/02/2000 | WO2000031055A1 Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione |
| 06/02/2000 | WO2000031051A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 06/02/2000 | WO2000031050A1 Quinoline and quinoxaline compounds |
| 06/02/2000 | WO2000031049A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors |
| 06/02/2000 | WO2000031048A1 N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| 06/02/2000 | WO2000031046A1 Novel acylguanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them |
| 06/02/2000 | WO2000031044A1 Iminoguanidine derivatives, preparation method, use as medicines |
| 06/02/2000 | WO2000030673A1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 06/02/2000 | WO2000030671A2 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 06/02/2000 | WO2000030668A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 06/02/2000 | WO2000030660A2 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
| 06/02/2000 | WO2000030615A1 Method of preparing stable suspensions of insoluble microparticles |
| 06/02/2000 | WO2000030590A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 06/02/2000 | WO2000030587A2 NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES |
| 06/02/2000 | WO2000014244A3 Treatment of cervical cancer |
| 06/02/2000 | WO1999062942A3 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
| 06/02/2000 | WO1999061097A9 Alpha emitting constructs and uses thereof |
| 06/02/2000 | CA2352665A1 Amino- and mercurio-substituted 4',5'-dihydropsoralens and therapeutical uses thereof |
| 06/02/2000 | CA2352599A1 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 06/02/2000 | CA2352584A1 Quinoline and quinoxaline compounds |
| 06/02/2000 | CA2352583A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors |
| 06/02/2000 | CA2352477A1 Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof |
| 06/02/2000 | CA2352261A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 06/02/2000 | CA2352043A1 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 06/02/2000 | CA2351872A1 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption |
| 06/02/2000 | CA2351733A1 Nf-kb activation inhibitors, and their pharmaceutical uses |
| 06/02/2000 | CA2351679A1 Prostaglandin conjugates for treating or preventing bone disease |
| 06/02/2000 | CA2351630A1 Vector |
| 06/02/2000 | CA2351361A1 Gtpase associated proteins |
| 06/02/2000 | CA2351354A1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 06/02/2000 | CA2351311A1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 06/02/2000 | CA2351061A1 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | CA2350969A1 Compounds having cytokine inhibitory activity |
| 06/02/2000 | CA2350759A1 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | CA2350758A1 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | CA2350755A1 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | CA2350753A1 Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | CA2350395A1 Nucleotide and protein sequences of nogo genes and methods based thereon |
| 06/02/2000 | CA2350189A1 Recombinant methods and materials for producing epothilone and epothilone derivatives |
| 06/02/2000 | CA2350066A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | CA2349721A1 N-¬4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl|-acrylamide, an irreversible inhibitor of tyrosine kinases |
| 06/02/2000 | CA2349290A1 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof |
| 06/02/2000 | CA2291880A1 Novel derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives |
| 05/31/2000 | EP1004584A2 Pyranoquinoline derivatives as inhibitors of cell proliferation |
| 05/31/2000 | EP1004581A2 Process for the preparation of thalidomide |
| 05/31/2000 | EP1004580A2 Imides as inhibitors of TNF alpha |
| 05/31/2000 | EP1004578A2 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| 05/31/2000 | EP1004572A2 Amines as inhibitors of TNF alpha |
| 05/31/2000 | EP1004319A1 Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors |
| 05/31/2000 | EP1004299A1 Antigen inducers, vaccine precursors, vaccines, antibodies, neutralizing antibodies, antitoxins, idiotypic antibodies, and anti-idiotypic antibodies induced by the idiotypic antibodies |
| 05/31/2000 | EP1004022A1 Methods and compositions for overcoming resistance to biologic and chemotherapy |
| 05/31/2000 | EP1003916A1 Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
| 05/31/2000 | EP1003880A2 Human ubiquitin carrier protein e2-like protein and cyclin b-like protein |
| 05/31/2000 | EP1003858A1 New human growth regulator protein |
| 05/31/2000 | EP1003857A2 Secreted proteins and polynucleotides encoding them |
| 05/31/2000 | EP1003856A1 Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| 05/31/2000 | EP1003783A2 Lipoprotein-regulating medicaments |
| 05/31/2000 | EP1003782A1 Ligand for herpes simplex virus entry mediator and methods of use |
| 05/31/2000 | EP1003780A1 Human f11 antigen: a cell surface receptor involved in platelet aggregation |
| 05/31/2000 | EP1003774A1 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 |
| 05/31/2000 | EP1003773A1 Ctl epitopes from ebv |
| 05/31/2000 | EP1003771A1 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances |
| 05/31/2000 | EP1003770A1 Secreted proteins and polynucleotides encoding them |
| 05/31/2000 | EP1003769A1 Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| 05/31/2000 | EP1003763A1 83 human secreted proteins |
| 05/31/2000 | EP1003750A1 Methods of preparing and purifying 9-nitro-20-camptothecin |
| 05/31/2000 | EP1003746A1 Purine inhibitor of protein kinases, g proteins and polymerases |
| 05/31/2000 | EP1003745A1 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
| 05/31/2000 | EP1003740A2 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagoists |
| 05/31/2000 | EP1003721A1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases |
| 05/31/2000 | EP1003720A1 Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| 05/31/2000 | EP1003559A2 Immobilization of vitamin a acid by cationic polyelectrolytes |
| 05/31/2000 | EP1003548A1 A method of inducing a ctl response |
| 05/31/2000 | EP1003543A1 Apoptosis-inducing gelsolin sequences |
| 05/31/2000 | EP1003536A1 Immunostimulatory and metastasis inhibiting fermented vegetal material |
| 05/31/2000 | EP1003534A1 Reovirus for the treatment of neoplasia |
| 05/31/2000 | EP1003533A1 Use of herpes vectors for tumor therapy |
| 05/31/2000 | EP1003525A1 Composition and method for regulating cell proliferation and cell death |
| 05/31/2000 | EP1003524A1 New formulation |
| 05/31/2000 | EP1003523A1 Method of treatment of liver tumours and pharmaceutical compositions for use therein |
| 05/31/2000 | EP1003521A1 Methods to potentiate intravenous estramustine phosphate |
| 05/31/2000 | EP1003516A1 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects |
| 05/31/2000 | EP1003498A1 Di-aryl ethers and their derivatives as anti-cancer agents |
| 05/31/2000 | EP1003496A1 Method for chemoprevention of prostate cancer |
| 05/31/2000 | EP1003492A2 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins |
| 05/31/2000 | EP1003480A1 Conjugated peptide nucleic acids having enhanced cellular uptake |
| 05/31/2000 | EP1003374A4 Inhibitors of farnesyl-protein transferase |
| 05/31/2000 | EP1003374A1 Inhibitors of farnesyl-protein transferase |
| 05/31/2000 | EP0865428B1 Vitamin d analogues |
| 05/31/2000 | EP0820448B1 Novel taxoids, preparation thereof, and pharmaceutical compositions containing same |
| 05/31/2000 | EP0746337B1 Verotoxin pharmaceutical compositions and medical treatments thereof |
| 05/31/2000 | EP0627921B1 Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
| 05/31/2000 | DE19856475A1 Nichtsteroidale Entzündungshemmer Nonsteroidal anti-inflammatory drugs |
| 05/31/2000 | CN1255164A Modified antisense nucleotides complementary to section of human Ha-Ras gene |
| 05/31/2000 | CN1255163A Compounds |